Injectable Maltodextrin-Based Micelle/Hydrogel Composites for Simvastatin-Controlled Release

Biomacromolecules. 2018 Dec 10;19(12):4554-4564. doi: 10.1021/acs.biomac.8b01234. Epub 2018 Nov 20.

Abstract

Injectable hydrogels have shown great potential in bone tissue engineering. Simvastatin (SIM), a common hypolipidemic drug, has been suggested as a potential agent to promote bone regeneration. However, due to its hydrophobic nature, the compatibility between SIM and hydrogels is rather poor, thereby greatly affecting the drug release behavior, the mechanical properties, and dimensional stability of the hydrogels. Herein, we presented a novel design to entrap SIM in an injectable maltodextrin-based micelle/hydrogel composite system. Maltodextrin-based micelles were prepared to solubilize and encapsulate SIM. The SIM-loaded aldehyde-modified micelles were anchored to the hydrogel network and served as a cross-linker to realize improved mechanical strength of hydrogel, controlled release, and osteogenic capability of SIM. In all, this study demonstrated a strategy to incorporate drug loaded carriers into hydrogels for drug delivery and tissue engineering applications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Regeneration / drug effects*
  • Delayed-Action Preparations / chemistry
  • Delayed-Action Preparations / pharmacology
  • Drug Carriers / chemistry
  • Drug Carriers / therapeutic use
  • Drug Delivery Systems*
  • Humans
  • Hydrogel, Polyethylene Glycol Dimethacrylate / chemistry*
  • Hydrogel, Polyethylene Glycol Dimethacrylate / therapeutic use
  • Micelles
  • Osteogenesis / drug effects
  • Polysaccharides / chemistry
  • Polysaccharides / pharmacology
  • Simvastatin / chemistry
  • Simvastatin / pharmacology*

Substances

  • Delayed-Action Preparations
  • Drug Carriers
  • Micelles
  • Polysaccharides
  • Hydrogel, Polyethylene Glycol Dimethacrylate
  • maltodextrin
  • Simvastatin